FDA Frowns on Evolus' Botox Rival

May 15, 2018

The U.S Food and Drug Administration did not approve DWP-450, Evolus Inc's rival product to Allergan Plc's Botox, due to chemistry and manufacturing issues.

As a result, the company pushed its estimate for the launch of the drug to the spring of next year. Read more here.

Facebook Comments


We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free